Kidney Cancer Drugs Market is Witnessing Rapid Growth with Pfizer and Merck KGaA Receiving the U.S. FDA Approval for immunotherapy Bavencio (avelumab) with Inlyta (axitinib) for advanced renal cell carcinoma (RCC)
Kidney cancer is cancer that arises within
the kidneys. Renal cell malignant neoplastic disease (RCC), additionally
referred to as excretory organ cell cancer or excretory organ cell glandular
carcinoma, is that the commonest sort of urinary organ cancer concerning nine
out of ten urinary organ cancers are excretory organ cell carcinomas.
Growing prevalence of kidney cancer
or renal cancer is expected to drive growth of the global kidney cancer drugs
market. According to the American Cancer Society, around 76,080 new cases of
kidney cancer, which is 48,780 in men and 27,300 in women, are estimated to be
diagnosed in 2021 in the U.S. Furthermore, around 13,780, which is 8,790 men
and 4,990 women, are estimated to die from this disease in 2021. According to
the World Cancer Research Fund, Belarus had the highest rate of kidney cancer
in 2018, followed by Latvia. Such a high incidence of kidney cancer has
increased the demand for relevant medications and treatment options. Some drugs
such as Everolimus (Afinitor) are used to treat advanced kidney cancers along
with lenvatinib when other drugs such as sunitinib and sorafenib have been
tried. Thus, such factors are expected to drive growth of the global kidney
cancer drugs market. Furthermore, the large availability of novel drugs and
the presence of a strong pipeline is expected to propel the global kidney
cancer drugs market growth in the near future.
However, the high cost of drugs and
uncertain reimbursement policies is expected to restrain growth of the global
kidney cancer drugs market. Furthermore, continuous research and development
activities can present lucrative growth opportunities in the global kidney
cancer drugs market. Among regions, North America is expected to witness
significant growth in the global kidney cancer drugs market. This is owing to
the presence of key manufacturers such as Pfizer and Novartis and increased
adoption of therapeutics in the region. Furthermore, Asia Pacific is expected
to register a robust growth rate, owing to proactive government support
targeting biotechnology in emerging economies such as China and Japan.
Key companies involved in the global
kidney cancer drugs market are Bayer, Pfizer, Novartis, Eisai, Exelixis,
Bristol-Myers Squibb, Genentech (Roche), and
Prometheus Labs.
For instance, in May 2019, Pfizer and Merck KGaA received the U.S. Food and Drug Administration (FDA) approval for their immunotherapy Bavencio (avelumab) with Inlyta (axitinib) for advanced renal cell carcinoma (RCC).
Comments
Post a Comment